GLP-1 receptor agonists have transformed the treatment of diabetes and obesity and generated one of the fastest-growing litigation dockets in the country. At an upcoming American Bar Association (ABA) program, a panel that includes HeplerBroom attorney Emilee Bramstedt will provide a comprehensive update on GLP-1 litigation, including the status of multi-district litigation, key rulings on causation and warning claims, and the science behind alleged injuries. The session is part of ABA’s 2026 Products Liability & Life Sciences Regional CLE Program, which will be held in Philadelphia October 21-22. More information about the program is available on ABA’s website.
Bramstedt, an associate in the firm’s Edwardsville office, has defended clients ranging from Fortune 500 companies to small businesses and individuals in matters involving pharmaceuticals, medical devices, and other product liability matters. She has experience handling a variety of legal issues, including complex multiparty class actions.